Accessibility Statement

2024YIR-Lilly.com-Wireframe PatientStat



The Power of Music

Music isn’t just a love for Myra Garcia — it sustains her. Now living with early Alzheimer’s disease, her passion for song keeps her heart full and her life active.


Waiting on a Breakthrough

Through advancements in genetic medicines, we’re working to give new hope to people–like Bill — living with Parkinson’s disease.


Living with OSA: Edgar's Story

Like Edgar, many people are unaware of their breathing interruptions during sleep. Working to dispel misconceptions, it’s time to learn more about obstructive sleep apnea.

Additional Resources



Lilly Cautionary and Other Statements

The statements made in the 2024 Year in Review may contain forward-looking statements that are based on management’s current expectations and assumptions, but actual results may di­ffer materially due to various factors. Words such as “estimate”, “project”, “intend”, “expect”, “believe”, “target”, “anticipate”, "may", "could", "aim", "seek", "will", "continue" and similar expressions are intended to identify forward-looking statements. However, by their nature, forward-looking statements are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Certain important factors that could cause actual results to di­ffer, possibly materially, from expectations or estimates reflected in such forward-looking statements can be found in the “Risk Factors” and “Forward-Looking Statements” sections included in the company’s Annual Report on Form 10-K for the year ended December 31, 2024, and may be further updated by any subsequent Forms 10-Q or 8-K filed with the Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements except as required by applicable law.

References to information in this report should not be construed as a characterization regarding the materiality of such information to the company’s financial results or operations. Lilly follows structured processes to collect, evaluate, calculate and validate the environmental, social impact and governance data included in this report. The data presented in this report is collected using various methodologies, which in some instances are based on assumptions and estimates in which there are inherent uncertainties and limitations, such as information collected from third-party sources and operations outside of Lilly’s control. While the company believes such information is reasonably accurate and is based on reasonable principles and methodology, the third-party collection of this data is beyond its direct control. In addition, any changes in methodology may result in material changes to the calculations and may result in the current and previous periods being adjusted. Furthermore, the achievement of certain sustainability goals and targets may be dependent on the actions of Lilly’s partners, suppliers and other third parties, all of which are outside of its control.

Certain financial information in this Year in Review is presented on a non-GAAP basis; these non-GAAP measures should be referred to in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP.

All trademarks or trade names referred to herein are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referred to herein, the property of their respective owners. Solely for convenience, the trademarks and trade names are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. Find more detail on Lilly’s sustainability priorities, strategies, and operations at lilly.com.